Shifting EU Treatment Paradigms In CLL
Fixed Duration Combo Of Venetoclax And Obinutuzumab Arrives
Executive Summary
The CLL market segment in the EU will now include a first-line combination therapy of AbbVie’s venetoclax and Roche’s obinutuzumab, which has recently been approved by the European Commission.